XML 68 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Fair value measurement and Other non-operating (losses) / gains - BMS warrants (Details)
$ in Thousands
 12 Months Ended
Dec. 01, 2020
USD ($)
item
Dec. 31, 2022
USD ($)
item
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Collaboration arrangements          
Number of warrant types   2      
Number of collaboration targets 4        
Collaboration agreement, cash payable | $ $ 70,000        
Fair value of derivative financial instruments | $   $ 35,316 $ 32,347 $ 2,645 $ 3,075
Fair value of the derivative financial liability | $   0      
CoC-payment          
Collaboration arrangements          
Gain (Loss) from the recognition of the derivative financial liability | $     (200) (2,600)  
Other nonoperating (losses) / gains | CoC-payment          
Collaboration arrangements          
Gain (Loss) from the recognition of the derivative financial liability | $   $ 2,800      
Non-current liabilities          
Collaboration arrangements          
Fair value of the derivative financial liability | $     $ 2,800    
BMS arrangement          
Collaboration arrangements          
Number of collaboration targets   4      
BMS arrangement | Bristol Myers Squibb          
Collaboration arrangements          
Number of collaboration targets   4      
BMS arrangement | Bristol Myers Squibb | Maximum          
Collaboration arrangements          
Number of collaboration targets 4        
BMS Warrants | Fair value hierarchy Level 3          
Collaboration arrangements          
Gain (Loss) recorded due to changes in fair value of derivative asset | $       $ 3,100  
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]       Other Nonoperating Income (Expense).  
BMS Warrants | BMS arrangement          
Collaboration arrangements          
Gain (Loss) recorded due to changes in fair value of derivative asset | $       $ 800  
Collaboration Agreement, If 70 Million Is Greater Than Five Percent Of Net Proceeds | Derecognition Of Warrants          
Collaboration arrangements          
Threshold percentage of net proceeds 5.0        
Percentage Of net proceeds payable 5        
Collaboration Agreement, If 70 Million Is Lesser Than One Percent Of Net Proceeds | Derecognition Of Warrants          
Collaboration arrangements          
Threshold percentage of net proceeds 1        
Percentage Of net proceeds payable 1        
Bristol Myers Squibb | uniQure N.V. | First Six New Targets Or Designation Of Sixth Target | BMS Warrants          
Collaboration arrangements          
Ownership percentage required per agreement   14.90%      
Bristol Myers Squibb | uniQure N.V. | First Six New Targets Or Designation Of Sixth Target | BMS Warrants | Minimum          
Collaboration arrangements          
Number of collaboration targets   6      
Bristol Myers Squibb | uniQure N.V. | First Six New Targets Or Designation Of Sixth Target | BMS Warrants | Maximum          
Collaboration arrangements          
Number of collaboration targets   7      
Bristol Myers Squibb | uniQure N.V. | First Nine New Targets Or Designation Of Ninth Target | BMS Warrants          
Collaboration arrangements          
Ownership percentage required per agreement   19.90%      
Bristol Myers Squibb | uniQure N.V. | First Nine New Targets Or Designation Of Ninth Target | BMS Warrants | Minimum          
Collaboration arrangements          
Number of collaboration targets   9      
Bristol Myers Squibb | uniQure N.V. | First Nine New Targets Or Designation Of Ninth Target | BMS Warrants | Maximum          
Collaboration arrangements          
Number of collaboration targets   10